Trial intelligence / Profile preview

Gemcitabine/Carboplatin vs Gemcitabine/Paclitaxel in Stage I-II NSCLC

NCT00191256Phase 2Completed

Sponsor
Eli Lilly and Company
Start
Jun 2001
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of gemcitabine in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Jun 2001; status: completed.

02

Drugs

gemcitabine
03

Conditions

non-small cell lung cancer (NSCLC)

Beyond the preview

Go deeper on NCT00191256.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00191256.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call